📊 MPLT Key Takeaways
Is MapLight Therapeutics, Inc. (MPLT) a Good Investment?
MapLight Therapeutics is a pre-revenue pharmaceutical company with severe cash burn and minimal path to profitability in the near term. Operating losses of $169.1M against only $46.7M in cash reserves indicate the company is in critical funding distress and will require immediate capital raises or significant operational changes to avoid insolvency.
MapLight Therapeutics is a pre-revenue biotech with a debt-free balance sheet and sizable assets, but losses and cash burn have accelerated while revenue remains absent. Despite a very high current ratio, cash and equivalents cover only a fraction of annual operating outflows, implying near-term financing needs. Until sustainable funding or non-dilutive revenue emerges, fundamentals skew negative.
Why Buy MapLight Therapeutics, Inc. Stock? MPLT Key Strengths
- Strong balance sheet with $458.4M stockholders equity and zero long-term debt provides flexibility for capital restructuring
- Exceptional liquidity ratios (20.01x current and quick ratios) indicate no immediate short-term payment obligations
- Recent insider activity with 21 Form 4 filings in last 90 days suggests ongoing company developments
- Debt-free capital structure (0.00x D/E)
- Exceptional liquidity (current ratio ~20x)
- Large asset base relative to liabilities ($479.5M vs $21.1M)
MPLT Stock Risks: MapLight Therapeutics, Inc. Investment Risks
- No revenue generation indicates failed or non-existent commercialization of pipeline; company has not achieved clinical or commercial viability
- Annual operating cash burn of $138.1M with only $46.7M cash on hand means runway is critically short (approximately 4 months) without additional funding
- Net losses accelerating (-107.7% YoY change in net income) with diluted EPS of -$18.56 demonstrates worsening financial deterioration and shareholder value destruction
- Negative ROE of -35.2% and ROA of -33.6% confirm company is destroying shareholder capital at alarming rates
- Pre-revenue biotech model carries extreme binary risk with no evidence of successful product development or near-term revenue potential
- Worsening losses (-$161M net; -107.7% YoY)
- High cash burn vs cash on hand (FCF -$138.6M vs $46.7M cash)
- No revenue; elevated dilution/financing risk
Key Metrics to Watch
- Quarterly cash runway and burn rate trajectory - critical for survival assessment
- Evidence of clinical trial progress, regulatory approvals, or partnership announcements indicating revenue potential
- Capital raise activities and terms - dilution and pricing will signal investor confidence levels
- Operating expense reductions and path to profitability milestones
- Cash, marketable securities, and quarterly operating cash burn (runway)
- R&D expense and share count/dilution from capital raises
MapLight Therapeutics, Inc. (MPLT) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 20.01x current ratio provides a solid financial cushion.
MPLT Profit Margin, ROE & Profitability Analysis
MPLT vs Healthcare Sector: How MapLight Therapeutics, Inc. Compares
How MapLight Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MapLight Therapeutics, Inc. Stock Overvalued? MPLT Valuation Analysis 2026
Based on fundamental analysis, MapLight Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MapLight Therapeutics, Inc. Balance Sheet: MPLT Debt, Cash & Liquidity
MPLT Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: MapLight Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-105.38 indicates the company is currently unprofitable.
MPLT Revenue Growth, EPS Growth & YoY Performance
MapLight Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
MPLT SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for MapLight Therapeutics, Inc. (CIK: 0001770069)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MPLT
What is the AI rating for MPLT?
MapLight Therapeutics, Inc. (MPLT) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (SELL) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MPLT's key strengths?
Claude: Strong balance sheet with $458.4M stockholders equity and zero long-term debt provides flexibility for capital restructuring. Exceptional liquidity ratios (20.01x current and quick ratios) indicate no immediate short-term payment obligations. ChatGPT: Debt-free capital structure (0.00x D/E). Exceptional liquidity (current ratio ~20x).
What are the risks of investing in MPLT?
Claude: No revenue generation indicates failed or non-existent commercialization of pipeline; company has not achieved clinical or commercial viability. Annual operating cash burn of $138.1M with only $46.7M cash on hand means runway is critically short (approximately 4 months) without additional funding. ChatGPT: Worsening losses (-$161M net; -107.7% YoY). High cash burn vs cash on hand (FCF -$138.6M vs $46.7M cash).
What is MPLT's revenue and growth?
MapLight Therapeutics, Inc. reported revenue of N/A.
Does MPLT pay dividends?
MapLight Therapeutics, Inc. does not currently pay dividends.
Where can I find MPLT SEC filings?
Official SEC filings for MapLight Therapeutics, Inc. (CIK: 0001770069) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MPLT's EPS?
MapLight Therapeutics, Inc. has a diluted EPS of $-18.56.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MPLT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, MapLight Therapeutics, Inc. has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MPLT stock overvalued or undervalued?
Valuation metrics for MPLT: ROE of -35.2% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MPLT stock in 2026?
Our dual AI analysis gives MapLight Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MPLT's free cash flow?
MapLight Therapeutics, Inc.'s operating cash flow is $-138.1M, with capital expenditures of $473.0K.
How does MPLT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -35.2% (avg: 15%), current ratio 20.01 (avg: 2).